Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Bedaquiline’s Safety Profile Monitoring in India: Considerations for Future - A Systematic Review

Author(s): Pugazhenthan Thangaraju*, Hemasri Velmurugan and Sree Sudha Tanguturi Yella

Volume 19, Issue 1, 2024

Published on: 24 February, 2023

Page: [24 - 32] Pages: 9

DOI: 10.2174/1574886318666230119102506

Price: $65

conference banner
Abstract

Background: Tuberculosis is still one of the top causes of infection-related death globally. Drug-resistant tuberculosis has a high mortality rate and is still a serious public health concern around the world. The appearance of multidrug-resistant and extensively drug-resistant strains of tuberculosis has increased the need for new therapeutic options against these strains. Most of the drugs used to treat them have been poorly tested and have serious negative effects. Patients with drug-resistant tuberculosis have been fighting for access to experimental medications, particularly bedaquiline.

Objective: The study aimed to summarise the existing evidence of bedaquiline's safety on drugresistant tuberculosis treatment outcome and look for bedaquiline-related adverse drug reactions in the Pharmacovigilance Programme of India and World Health Organisation - Uppsala Monitoring Centre database.

Methods: We searched the PubMed database for relevant studies on the safety profile of bedaquiline used in the treatment of drug-resistant tuberculosis and bedaquiline-related adverse drug reactions in the Pharmacovigilance Programme of India and World Health Organisation - Uppsala Monitoring Centre database published up to April 25, 2022.

Results: A total of 190 abstracts were identified through the Pubmed database. In a list of 157 fulltext eligible articles assessed, 149 were excluded as they did not meet the inclusion criteria. The complete articles of the remaining 8 studies were further evaluated. There were 4 prospective cohorts, 2 retrospective cohorts, and 2 case series.

Conclusion: Pharmacovigilance and medication safety monitoring of newer treatments, like bedaquiline, are critical for enhancing treatment support and adherence, especially among drugresistant tuberculosis patients.

« Previous Next »
Graphical Abstract

[1]
Bloom BR, Atun R, Cohen T, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, Eds. Major Infectious Diseases. 3rd ed. Washington, DC: The International Bank for Reconstruction and Development/The World Bank 2017.
[http://dx.doi.org/10.1596/978-1-4648-0524-0_ch11]
[2]
Kawabata Y. Pathogenesis of tuberculosis. Jpn J Clin Med 1998; 56(12): 3041-6.
[PMID: 9883606]
[3]
World Health Organization. Global tuberculosis report 2021. 2022. Available from: https://www.who.int/publications/i/item/9789240037021 (Assessed on: 25, April 2022).
[4]
Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: Current status and future perspectives. J Glob Antimicrob Resist 2021; 25: 48-59.
[http://dx.doi.org/10.1016/j.jgar.2021.02.017] [PMID: 33684606]
[5]
Wang MG, Wu SQ, He JQ. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: A systematic review and meta-analysis. BMC Infect Dis 2021; 21(1): 970.
[http://dx.doi.org/10.1186/s12879-021-06666-8] [PMID: 34535090]
[6]
Pontali E, Sotgiu G, D’Ambrosio L, Centis R, Migliori GB. Bedaquiline and multidrug-resistant tuberculosis: A systematic and critical analysis of the evidence. Eur Respir J 2016; 47(2): 394-402.
[http://dx.doi.org/10.1183/13993003.01891-2015] [PMID: 26828052]
[7]
Sachdeva KS, Arora N, Solanki R, et al. Strengthened capacity of India’s bedaquiline Conditional Access Programme for introducing new drugs and regimens. Int J Tuberc Lung Dis 2020; 24(10): 1067-72.
[http://dx.doi.org/10.5588/ijtld.20.0136] [PMID: 33126941]
[8]
Provisional CDC. Guidance for the Use of Pretomanid as part of a Regimen [bedaquiline, pretomanid, and linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease. CDC. 2022. Available from: https://www.cdc.gov/tb/topic/drtb/bpal/default.htm#:~:text=Tuberculosis-,Provisional%20CDC%20Guidance%20for%20the%20Use%20of%20Pretomanid%20as%20part,Treat%20Drug%2DResistant%20Tuberculosis%20Disease&text=FDA%20approved%20the%20use%20of,(BPaL)%20in%20August%202019 (Assessed on 25, April 2022).
[9]
Indian Pharmacopoeia Commission (IPC). Pharmacovigilance Program of India (PvPI). Annual Performance Report 2018-2019. 2022. Available from: https://ipc.gov.in/images/e-PvPI_Annual_ Performance_Report_2018-19.pdf (Assessed on 25, April 2022).
[10]
India set to roll out bedaquiline to combat extensively drugresistant TB, The Pharma Letter 2022. Available from: www.thepharmaletter.com/article/india-set-to-roll-out-bedaquiline-to-combat-extensively-drug-resistant-tb (Assessed on 25, April 2022).
[11]
Villellas C, Coeck N, Meehan CJ, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother 2016; 72(3): dkw502.
[http://dx.doi.org/10.1093/jac/dkw502] [PMID: 28031270]
[12]
World Health Organization (WHO). The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, Switzerland: WHO 2013. Available from: https://apps.who.int/iris/bitstream/handle/10665/84879/9789241505482_eng.pdf?sequence=1 (Assessed on 25, April 2022).
[13]
India TB report 2022. National Tuberculosis Elimination Program (NTEP). Ministry of Health and Family Welfare (MOHFW). 2022. Available from: https://tbcindia.gov.in/WriteReadData/IndiaTBReport2022/TBAnnaulReport2022.pdf (Accessed on: March 24, 2022).
[14]
The US Food and Drug Administration (FDA): Bedaquiline. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf (Accessed on: 25, April 2022).
[15]
Quan D, Nagalingam G, Payne R, Triccas JA. New tuberculosis drug leads from naturally occurring compounds. Int J Infect Dis 2017; 56: 212-20.
[http://dx.doi.org/10.1016/j.ijid.2016.12.024] [PMID: 28062229]
[16]
Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis 2021; 21(7): 975-83.
[http://dx.doi.org/10.1016/S1473-3099(20)30770-2] [PMID: 33587897]
[17]
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371(8): 723-32.
[http://dx.doi.org/10.1056/NEJMoa1313865] [PMID: 25140958]
[18]
Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J 2018; 51(5): 1800544.
[http://dx.doi.org/10.1183/13993003.00544-2018] [PMID: 29700106]
[19]
Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018; 6(9): 699-706.
[http://dx.doi.org/10.1016/S2213-2600(18)30235-2] [PMID: 30001994]
[20]
Das M, Dalal A, Laxmeshwar C, et al. One step forward: Successful end-of-treatment outcomes of patients with drug-resistant tuberculosis who received concomitant bedaquiline and delamanid in Mumbai, India. Clin Infect Dis 2021; 73(9): e3496-504.
[http://dx.doi.org/10.1093/cid/ciaa1577] [PMID: 33079176]
[21]
Barvaliya SV, Desai MK, Panchal JR, Solanki RN. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients. Indian J Tuberc 2020; 67(2): 222-30.
[http://dx.doi.org/10.1016/j.ijtb.2020.03.002] [PMID: 32553316]
[22]
Shah I, Gandhi S, Shetty NS. Bedaquiline and delamanid in children with XDR tuberculosis: What is prolonged QTc? Pediatr Infect Dis J 2020; 39(6): 512-3.
[http://dx.doi.org/10.1097/INF.0000000000002601] [PMID: 32032176]
[23]
Das M, Mamnoon F, Mansoor H, et al. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India. Int J Tuberc Lung Dis 2020; 24(12): 1265-71.
[http://dx.doi.org/10.5588/ijtld.20.0165] [PMID: 33317670]
[24]
Sarin R, Vohra V, Singla N, et al. Early efficacy and safety of Bedaquiline and Delamanid given together in a “Salvage Regimen” for treatment of drug-resistant tuberculosis. Indian J Tuberc 2019; 66(1): 184-8.
[http://dx.doi.org/10.1016/j.ijtb.2019.02.006] [PMID: 30878066]
[25]
Sarin R, Singla N, Vohra V, et al. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India. Indian J Tuberc 2019; 66(1): 209-13.
[http://dx.doi.org/10.1016/j.ijtb.2019.02.009] [PMID: 30878071]
[26]
Salhotra VS, Sachdeva KS, Kshirsagar N, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. Indian J Tuberc 2020; 67(1): 29-37.
[http://dx.doi.org/10.1016/j.ijtb.2019.10.002] [PMID: 32192613]
[27]
Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis 2014; 18(11): 1315-8.
[http://dx.doi.org/10.5588/ijtld.14.0284] [PMID: 25299863]
[28]
Guidelines for Programmatic Management of Drug Resistant tuberculosis in India. 2021. Available from: https://tbcindia.gov.in/showfile.php?lid=3590
[29]
WHO Collaborating Centre for International Drug Monitoring. Uppsala Monitoring Centre. 2022. Available from: http://www.vigiaccess.org/ (Accessed on: 25, April 2022).
[30]
Lakshmanan M, Xavier AS. Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm 2013; 5(4): 112-5.
[http://dx.doi.org/10.1016/j.jyp.2013.12.002] [PMID: 24563587]
[31]
End TB. Project. EndTB clinical and programmatic guide for patient management with new TB drugs (version 4.0). End TB, 2018:1-69. 2022. Available from: https://samumsf.org/sites/default/files/2018-06/EndTB%20Guide% 20for%20New%20TB%20Drugs%20Version%204.0.pdf (Accessed on: 25, April 2022).
[32]
Patel H, Pawara R, Pawara K, Ahmed F, Shirkhedkar A, Surana S. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity. Tuberculosis (Edinb) 2019; 117: 79-84.
[http://dx.doi.org/10.1016/j.tube.2019.06.005] [PMID: 31378273]
[33]
Upadhayaya RS, Kulkarni GM, Vasireddy NR, et al. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Bioorg Med Chem 2009; 17(13): 4681-92.
[http://dx.doi.org/10.1016/j.bmc.2009.04.069] [PMID: 19457676]
[34]
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307(5707): 223-7.
[http://dx.doi.org/10.1126/science.1106753] [PMID: 15591164]
[35]
Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51(11): 4202-4.
[http://dx.doi.org/10.1128/AAC.00181-07] [PMID: 17709466]
[36]
Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020; 92: S15-25.
[http://dx.doi.org/10.1016/j.ijid.2020.01.042] [PMID: 32032752]
[37]
Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2019; 23(6): 645-62.
[http://dx.doi.org/10.5588/ijtld.18.0622] [PMID: 31315696]
[38]
Parmar MM, Sachdeva KS, Dewan PK, et al. Unacceptable treatment outcomes and associated factors among India’s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement. PLoS One 2018; 13(4): e0193903.
[http://dx.doi.org/10.1371/journal.pone.0193903] [PMID: 29641576]
[39]
Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort. Clin Infect Dis 2015; 60(2): 188-94.
[http://dx.doi.org/10.1093/cid/ciu786] [PMID: 25320286]
[40]
Achar J, Hewison C, Cavalheiro AP, et al. Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis. Emerg Infect Dis 2017; 23(10): 1711-3.
[http://dx.doi.org/10.3201/eid2310.170303] [PMID: 28758889]
[41]
Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: A multicentre study. Eur Respir J 2017; 49(5): 1700387.
[http://dx.doi.org/10.1183/13993003.00387-2017] [PMID: 28529205]
[42]
Jones J, Mudaly V, Voget J, Naledi T, Maartens G, Cohen K. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: An evaluation of spontaneously reported cases. BMC Infect Dis 2019; 19(1): 544.
[http://dx.doi.org/10.1186/s12879-019-4197-7] [PMID: 31221100]
[43]
Gaida R, Truter I, Peters CA. Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis. S Afr J Infect Dis 2020; 35(1): 23.
[http://dx.doi.org/10.4102/sajid.v35i1.23] [PMID: 34485463]
[44]
Ionescu AM, Mpobela Agnarson A, Kambili C, et al. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2018; 18(6): 677-89.
[http://dx.doi.org/10.1080/14737167.2018.1507821] [PMID: 30073886]
[45]
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization 2014.
[46]
Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J 2019; 54(6): 1901522.
[http://dx.doi.org/10.1183/13993003.01522-2019] [PMID: 31601711]
[47]
Rodriguez CA, Brooks MB, Guglielmetti L, et al. Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: A mixed-methods study. Public Health Action 2019; 9(1): 32-41.
[http://dx.doi.org/10.5588/pha.18.0078] [PMID: 30963040]
[48]
Borisov SE, D’Ambrosio L, Centis R, et al. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. J Infect 2019; 78(1): 35-9.
[http://dx.doi.org/10.1016/j.jinf.2018.08.003] [PMID: 30096332]
[49]
National workshop on pharmacovigilance of anti tubercular medicines in India. WHO. 2017. Available from: https://www.who.int/india/news/detail/12-07-2017-national-workshop-on-pharmacovigilance-of-anti-tubercular-medicines-in-india (Accessed on: 25, April 2022).

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy